Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

First Results of the Interdisciplinary Comprehensive Cancer Center Freiburg (CCCF) Tumor Board (TB) Multiple Myeloma (MM) Assessing TB-Questions, TB-Advice Adherence, TB-Satisfaction of Patients, Participants and Referring Physicians, Inclusion of Difficult-to-Treat-MM Pts in Clinical Trials (CT) and Patient Outcome

Ricarda Selder, Masa Pandurevic, Mandy-Deborah Möller, Johannes Waldschmidt, MD, Milena Pantic, Georg W. Herget, Karl Henne, Annette May, Martina Kleber, MD, Josefina Udi, MD, Gabriele Ihorst, Rainer Bredenkamp, Werner Vach, Justus Duyster, MD, Ralph Wäsch, MD, Monika Engelhardt, MD

Blood (2014) 124 (21): 2635.

https://doi.org/10.1182/blood.V124.21.2635.2635

Published: 2014

Journal Articles

Exosomes Secreted By Multiple Myeloma Cell Lines (MMCLs) and Bone Marrow Stromal Cells (BMSCs) Reciprocally Modulate Cell Adhesion and Impact on MM Cell Migration and Bortezomib-Induced Apoptosis

Josefina Udi, MD, Reinhard Voll, MD, Daniela Ureta, Margarita López, Ralph Wäsch, MD, Élida Álvarez, Monika Engelhardt, MD

Blood (2014) 124 (21): 5141.

https://doi.org/10.1182/blood.V124.21.5141.5141

Published: 2014

Journal Articles

Bone Marrow Interaction in Multiple Myeloma Pathogenesis: Phenotypical Analysis, Kinetics and Novel Therapy Approaches Based On CXCR4 Inhibition.

Johannes Waldschmidt, Dagmar Wider, Marie Follo, PhD, Josefina Udi, MD, Martina Kleber, Joschka Lorenz, Gabriele Ihorst, Ralph Wäsch, Monika Engelhardt

Blood (2012) 120 (21): 2450.

https://doi.org/10.1182/blood.V120.21.2450.2450

Published: 2012

Journal Articles

Multikinase Inhibitor Sorafenib Induces Apoptosis, CD138-Downregulation, Actin Depolymerization and Inhibition of M210B4-Triggered Chemotaxis in Multiple Myeloma Cell Lines and Synergyzes with Proteasome Inhibitor Bortezomib

Josefina Udi, MD, Dagmar Wider, Julie Catusse, PhD, Dominik Schnerch, MD, Marie Follo, PhD, Gabriele Ihorst, Ralph Waesch, MD, Monika Engelhardt, MD

Blood (2011) 118 (21): 2380.

https://doi.org/10.1182/blood.V118.21.2380.2380

Published: 2011

Journal Articles

Striking Anti-Multiple Myeloma (MM) Activity with the In Vitro Use of the Multikinase Inhibitor Sorafenib (S), Cytotoxic Synergy Between Bortezomib (B) and S, but Not Between B and Epigallocatechin-3-Gallate (EGCG; E) Enlarge the Present Knowledge In MM and Promise Novel Insights for Innovative Substance Exploitation In MM-Treatment

Josefina Udi, Dagmar Wider, Julie Catusse, Gabriele Ihorst, Dominik Schnerch, Marie Follo, Meike Burger, Ralph M. Waesch, MD, Monika Engelhardt

Blood (2010) 116 (21): 5020.

https://doi.org/10.1182/blood.V116.21.5020.5020

Published: 2010

Journal Articles

Use of Lenalidomide May Surmount the Adverse Prognosis Induced by Renal Impairment In Patients (pts) with Relapsed/Refractory Multiple Myeloma (MM)

Martina Kleber, Gabriele Ihorst, Josefina Udi, Bernd Koch, Monika Engelhardt

Blood (2010) 116 (21): 3042.

https://doi.org/10.1182/blood.V116.21.3042.3042

Published: 2010

Journal Articles

“Antitumor Activity of Novel Anti-MM Agents and Combinations, the Proteasome Inhibitor Bortezomib and Multikinase Inhibitor Sorafenib, Both Applied as Monotherapy and in Combination in NOD/SCID-IL2-Receptor-Gamma-chain −/− (NSG) Mice Using a Intratibial Tumor Dissemination approach”.

Julia Schüler, Dagmar Wider, Dietmar Pfeifer, Josefina Udi, Heinz-Herbert Fiebig, Ralph M. Waesch, Monika Engelhardt

Blood (2009) 114 (22): 4912.

https://doi.org/10.1182/blood.V114.22.4912.4912

Published: 2009

Journal Articles

In Vitro Assessment of Anti-Multiple Myeloma (MM)-Agents On Various MM-Cell Lines (MMCLs) with Use of Bortezomib, Sorafenib, Thalidomide, Lenalidomide and EpiGalloCatechin-3-Gallate (EGCG) Demonstrates to Be a Valuable Tool for the Thorough Analysis and Discovery of Innovative Anti-MM-Agents.

Josefina Udi, Dagmar Wider, Gabriele Ihorst, Julia Schüler, Ralph Wäsch, Monika Engelhardt

Blood (2009) 114 (22): 4922.

https://doi.org/10.1182/blood.V114.22.4922.4922

Published: 2009

Journal Articles

Higher Vascular Endothelial Growth Factor (VEGF) and Endothelial Progenitor Cells (EPCs) in Multiple Myeloma (MM) Patients (pts) as a Reflection of Their Governing Role in Pathological Angiogenesis: Comparison of VEGF and EPC Levels Between Healthy Donors (HD), MGUS and MM Pts and Correlation Analysis with MM Activity

Josefina Udi, Martina Kleber, Dagmar Wider, Ralph Wäsch, Monika Engelhardt

Blood (2008) 112 (11): 5132.

https://doi.org/10.1182/blood.V112.11.5132.5132

Published: 2008

NARROW

Exosomes Secreted By Multiple Myeloma Cell Lines (MMCLs) and Bone Marrow Stromal Cells (BMSCs) Reciprocally Modulate Cell Adhesion and Impact on MM Cell Migration and Bortezomib-Induced Apoptosis

Bone Marrow Interaction in Multiple Myeloma Pathogenesis: Phenotypical Analysis, Kinetics and Novel Therapy Approaches Based On CXCR4 Inhibition.

Multikinase Inhibitor Sorafenib Induces Apoptosis, CD138-Downregulation, Actin Depolymerization and Inhibition of M210B4-Triggered Chemotaxis in Multiple Myeloma Cell Lines and Synergyzes with Proteasome Inhibitor Bortezomib

Use of Lenalidomide May Surmount the Adverse Prognosis Induced by Renal Impairment In Patients (pts) with Relapsed/Refractory Multiple Myeloma (MM)

“Antitumor Activity of Novel Anti-MM Agents and Combinations, the Proteasome Inhibitor Bortezomib and Multikinase Inhibitor Sorafenib, Both Applied as Monotherapy and in Combination in NOD/SCID-IL2-Receptor-Gamma-chain −/− (NSG) Mice Using a Intratibial Tumor Dissemination approach”.

In Vitro Assessment of Anti-Multiple Myeloma (MM)-Agents On Various MM-Cell Lines (MMCLs) with Use of Bortezomib, Sorafenib, Thalidomide, Lenalidomide and EpiGalloCatechin-3-Gallate (EGCG) Demonstrates to Be a Valuable Tool for the Thorough Analysis and Discovery of Innovative Anti-MM-Agents.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only